Novel Therapeutic Options for Small Cell Lung Cancer
Purpose of Review The aim of this review is to focus on the recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential promising new treatment strategies, like targeting the DNA damage pathway, epigenetics, angiogenesis, and oncogenic drivers. Recent Findings In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Recently, numerous genomic alterations have been identified, and they may be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, SCLC-Y, SCLC-P). Summary SCLC accounts for 10-20% of all lung cancers, most patients have an extensive disease at the diagnosis, and it is characterized by poor prognosis. Despite the progresses in the knowledge of the disease, efficacious targeted treatments are still lacking. In the near future, the molecular characterisation of SCLC will be fundamental to find more effective treatment strategies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current oncology reports - 25(2023), 11 vom: 23. Okt., Seite 1277-1294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Canova, Stefania [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Immunotherapy |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s11912-023-01465-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053709136 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053709136 | ||
| 003 | DE-627 | ||
| 005 | 20231112064636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231112s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11912-023-01465-7 |2 doi | |
| 035 | |a (DE-627)SPR053709136 | ||
| 035 | |a (SPR)s11912-023-01465-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Canova, Stefania |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Therapeutic Options for Small Cell Lung Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Purpose of Review The aim of this review is to focus on the recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential promising new treatment strategies, like targeting the DNA damage pathway, epigenetics, angiogenesis, and oncogenic drivers. Recent Findings In the last few years, the addition of immunotherapy to chemotherapy has led to significant improvements in clinical outcomes in this complex neoplasia. Nevertheless, the prognosis remains dismal. Recently, numerous genomic alterations have been identified, and they may be useful to classify SCLC into different molecular subtypes (SCLC-A, SCLC-I, SCLC-Y, SCLC-P). Summary SCLC accounts for 10-20% of all lung cancers, most patients have an extensive disease at the diagnosis, and it is characterized by poor prognosis. Despite the progresses in the knowledge of the disease, efficacious targeted treatments are still lacking. In the near future, the molecular characterisation of SCLC will be fundamental to find more effective treatment strategies. | ||
| 650 | 4 | |a SCLC classification |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Target therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a PARP inhibitors |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Trevisan, Benedetta |4 aut | |
| 700 | 1 | |a Abbate, Maria Ida |4 aut | |
| 700 | 1 | |a Colonese, Francesca |4 aut | |
| 700 | 1 | |a Sala, Luca |4 aut | |
| 700 | 1 | |a Baggi, Alice |4 aut | |
| 700 | 1 | |a Bianchi, Sofia Paola |4 aut | |
| 700 | 1 | |a D’Agostino, Anna |4 aut | |
| 700 | 1 | |a Cortinovis, Diego Luigi |0 (orcid)0000-0001-7611-7369 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d Philadelphia, Pa. : Current Science, Inc., 1999 |g 25(2023), 11 vom: 23. Okt., Seite 1277-1294 |w (DE-627)SPR022982957 |w (DE-600)2054295-1 |x 1534-6269 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:11 |g day:23 |g month:10 |g pages:1277-1294 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11912-023-01465-7 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 11 |b 23 |c 10 |h 1277-1294 | ||